LongeVC invests in Canadian medtech Proton Intelligence

Latvian LongeVC has invested in Canadian Proton Intelligence which develops non-invasive CKM for monitoring potassium levels in patients with kidney disease. The $6,95M round also included participation from Spanish We Venture Capital, Australian Tenmile and Trampoline Venture Partners, American SOSV and Exor Ventures, Japanese 15th Rock and others.

Proton Intelligence has developed CKM technology to provide physicians and patients with accurate, continuous potassium levels to treat patients with kidney disease. The company was founded by CEO Sahan Ranamuharachchi and COO Victor Cadarso in 2020 in Vancouver.

Founded in 2016 by Garri Zmudze, Sergey Jakimov, and Ilya Suharenko, LongeVC is a venture company with offices in Riga and Lugano (Switzerland). A €35M fund backs startups at the early and seed stage startups in the US and Europe.